Cargando…

Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer

OBJECTIVES: To investigate the association between intraprostatic, intratumoral maximum standardised uptake values (SUV(max)) on prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer (PCa) prior to robot‐assisted radical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bodar, Yves J.L., Veerman, Hans, Meijer, Dennie, de Bie, Katelijne, van Leeuwen, Pim J., Donswijk, Maarten L., van Moorselaar, R. Jeroen A., Hendrikse, N. Harry, Boellaard, Ronald, Oprea‐Lager, Daniela E., Vis, André N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315142/ https://www.ncbi.nlm.nih.gov/pubmed/35166426 http://dx.doi.org/10.1111/bju.15710

Ejemplares similares

The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography
por: Veerman, Hans, et al.
Publicado: (2022)

Higher Preoperative Maximum Standardised Uptake Values (SUV(max)) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [(68)Ga]Ga-PSMA-11 and [(18)F]DCFPyL Positron Emission Tomography/Computed Tomography
por: de Bie, Katelijne C. C., et al.
Publicado: (2023)

The clinical characteristics of patients with primary non‐prostate‐specific membrane antigen‐expressing prostate cancer on preoperative positron emission tomography/computed tomography
por: Veerman, Hans, et al.
Publicado: (2021)

Predicting early outcomes in patients with intermediate‐ and high‐risk prostate cancer using prostate‐specific membrane antigen positron emission tomography and magnetic resonance imaging
por: Meijer, Dennie, et al.
Publicado: (2021)

Management impact of (18)F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study
por: Meijer, Dennie, et al.
Publicado: (2021)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
por: Luining, Wietske I., et al.
Publicado: (2022)

Prospective analysis of clinically significant prostate cancer detection with [(18)F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study
por: Bodar, Yves J. L., et al.
Publicado: (2021)

Detection of prostate cancer with (18)F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial
por: Bodar, Y. J. L., et al.
Publicado: (2020)

External Validation of Two Nomograms Developed for (68)Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer (18)F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
por: Luiting, Henk B., et al.
Publicado: (2021)

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels
por: Meijer, Dennie, et al.
Publicado: (2019)

Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers
por: Luining, Wietske I., et al.
Publicado: (2021)

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature
por: Luiting, Henk B., et al.
Publicado: (2019)

Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
por: Jansen, B. H. E., et al.
Publicado: (2020)

Clinical verification of (18)F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer
por: Meijer, Dennie, et al.
Publicado: (2020)

Optimization and validation of (18)F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer
por: Luining, Wietske I., et al.
Publicado: (2023)

Comment on Rosenzweig et al. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates. J. Pers. Med. 2022, 12, 410
por: Veerman, Hans, et al.
Publicado: (2022)

Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020)

Distribution of prostate cancer recurrences on gallium‐68 prostate‐specific membrane antigen ((68)Ga‐PSMA) positron‐emission/computed tomography after radical prostatectomy with pathological node‐positive extended lymph node dissection
por: Huits, Thijs H., et al.
Publicado: (2020)

Cylindroma, an uncommon presentation on (18)F-DCFPyL PET/CT
por: Koene, B. P. F., et al.
Publicado: (2020)

Dual-Phase PET-CT to Differentiate [(18)F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer
por: Oprea-Lager, Daniela E., et al.
Publicado: (2012)

Standardised Uptake Value in Organ Confined Prostate Cancer in 68-Ga- Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography Scan and its Correlation with Prostate Specific Antigen Level and Gleason Score
por: Ali*, Haider, et al.
Publicado: (2023)

Identifying Patients in Whom the Follow-Up Scheme after Robot-Assisted Radical Prostatectomy Could Be Optimized in the First Year after Surgery: Reducing Healthcare Burden
por: Veerman, Hans, et al.
Publicado: (2023)

Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
por: Wondergem, M., et al.
Publicado: (2019)

Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer
por: LIU, YIYAN
Publicado: (2014)

Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
por: Asokendaran, Marcus Edward, et al.
Publicado: (2019)

Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
por: Oprea-Lager, Daniela E., et al.
Publicado: (2021)

Making the Case for Prostate-Specific Membrane Antigen-Targeted Positron Emission Tomography/Computed Tomography in Suspected Prostate Cancer
por: Singh, Harmandeep
Publicado: (2020)

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options
por: Zuur, Lotte G., et al.
Publicado: (2023)

Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Dundee, Philip, et al.
Publicado: (2022)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan
por: Agarwal, Krishan Kant, et al.
Publicado: (2016)

Upcoming Role of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Detecting Occult Metastases in Prostate Cancer
por: Gupta, Parul, et al.
Publicado: (2019)

Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography
por: Gupta, Manoj, et al.
Publicado: (2020)

State of the Art in Prostate-specific Membrane Antigen–targeted Surgery—A Systematic Review
por: Berrens, Anne-Claire, et al.
Publicado: (2023)

Diagnosis of prostatitis by 18-F-fluorodeoxyglucose positron emission tomography
por: Ho, Thien Anh, et al.
Publicado: (2009)

Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography
por: Jadvar, Hossein
Publicado: (2015)

Positron emission tomography in prostate cancer: An update on state of the art
por: Das, Chandan Jyoti, et al.
Publicado: (2018)

Occult Prostate Cancer Detected with 18F-Fluorocholine Positron Emission Tomography/Computed Tomography
por: Xie, Wanying, et al.
Publicado: (2014)

Spinal Tuberculosis Mimicking as Prostate Cancer Metastases in Ga-68 Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography
por: Gupta, Nitin, et al.
Publicado: (2020)

Solitary Metastasis of Prostatic Adenocarcinoma to the Testicle Detected by (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Deeb, Ibrahim Alsheikh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qv1751jaq7df5bdd4j75l5ikdm